MicroRNA-16-1 Inhibits Tumor Cell Proliferation and Induces Apoptosis in A549 Non-Small Cell Lung Carcinoma Cells

Weihua Wang,* Jie Chen,* Jinhua Dai,† Burong Zhang,* Feng Wang,* and Yizhe Sun‡

*Department of Clinical Laboratory, The Affiliated Hospital of School of Medicine of Ningbo University, Ningbo, Zhejiang, China
†Department of Clinical Laboratory, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China
‡Wuhan Hospital for the Prevention and Treatment of Occupational Disease, Wuhan, Hubei, China

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Plenty of microRNAs (miRs), except miR-16-1, have been reported to be associated with the initiation and progression of NSCLC. This study was aimed to explore the impacts of miR-16-1 on NSCLC cells. Human NSCLC cell line A549 was used, and the expression of miR-16-1 was up- or downregulated by transfecting with miR-16-1 mimics or inhibitors. Afterward, cell proliferation and apoptosis were detected using MTT assay, BrdU assay, and Annexin V/FITC Apoptosis Detection Kit. The expression changes of proliferation- and apoptosis-related factors were measured by Western blot. Results showed that miR-16-1 overexpression significantly inhibited cell proliferation and induced apoptosis when compared with the control group. Besides, miR-16-1 overexpression significantly upregulated the protein expressions of p27, Bax, procaspase 3, and cleaved caspase 3, whereas it downregulated Bcl-2. Conversely, miR-16-1 suppression affected NSCLC cell proliferation and apoptosis, and these protein expressions resulted in completely opposite impacts. In conclusion, miR-16-1 overexpression could inhibit cell proliferation and induce apoptosis via regulating the expression of p27, Bcl-2, Bax, and caspase 3 in NSCLC cells.

Key words: MicroRNA-16-1; Non-small cell lung cancer (NSCLC); Cell proliferation; Apoptosis

INTRODUCTION

Lung cancer is the most common cancer worldwide, and it is becoming the major reason for cancer death (1). Lung cancer consists of two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with NSCLC dominating over 80% of all lung cancer cases (2). Patients in early stages (I, II, or III-a) of NSCLC are generally treated with surgery, chemotherapy, radiation, or a combined modality approach (3). Patients with advanced or metastatic stage (III-b or IV) of NSCLC are often treated with systemic chemotherapy, but response and survival rates continue to be modest (4,5). Nowadays, the understanding of the molecular biology of NSCLC has been tremendously increased, and the molecular targeted therapy has been applied for treating NSCLC (1). Nonetheless, more efforts still need to be made in investigating a better understanding of NSCLC, so novel effective molecular targeted therapies can be designed and developed for treating this disease.

MicroRNAs (miRs) are endogenous approximately 22-nt RNAs that have been identified as one of the regulators in carcinogenesis (6–8). Several recent studies have demonstrated that many miRs, such as miR-499-5p (9), miR-187-3p (10), and miR-200 (11), are involved in the initiation and progression of NSCLC by regulating their target genes. miR-16-1 is one of the miRs and has been reported to be an important tumor suppressor in many cancer cells (12). For example, Zubillaga-Guerrero et al. demonstrated that miR-16-1 inhibits cervical cancer cell growth through modulating cell cycle process (13). Functional study has demonstrated that miR-16-1, together with miR-15a, suppresses gastric adenocarcinoma cell proliferation, monolayer colony formation, invasion, and migration (14). In addition, miR-16-1 is associated with the induction of acute lymphoblastic leukemia cell apoptosis (15), while the roles of miR-16-1 in NSCLC cells have not been well identified.

Therefore, the goal of this study was to better clarify the function of miR-16-1 on NSCLC cells and its possible associated mechanisms. Human NSCLC cell line A549 was used and transfected with miR-16-1 mimics or inhibitors. Then the impacts of miR-16-1 overexpression or suppression on A549 cell proliferation and apoptosis were measured. Moreover, expression changes of the
proliferation- and apoptosis-related factors were detected to reveal its possible function mechanisms. This study provides a basic understanding of miR-16-1 on NSCLC cells and offers evidence for its potential application in the treatment of NSCLC.

MATERIALS AND METHODS

Cell Culture and Transfection

Human NSCLC cell line A549 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen) at 37°C in 5% CO₂ (16). Cells in logarithmic phase were used for the further analysis.

For transfection, miR-16-1 mimics, inhibitors, and control were designed and produced from GenePharma (Shanghai, China). First, cells were seeded into 24-well plates for 24 h, and then were transfected with miR-16-1 mimics, inhibitors, or control, by using the Lipofectamine 2000 reagent (Invitrogen) according to the manual. Finally, the transfected cells were collected for further analyses.

MTT Assay

Cell viability was assessed using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay. In brief, transfected cells were implanted into 96-well plates at a density of 2 × 10³ cells/well. After culture for 1–5 days, 20 μl of MTT (Sigma-Aldrich, St. Louis, MO, USA) solution was added to each well and cultured for 4 h at 37°C. Finally, 150 μl of dimethyl sulfoxide (DMSO) was used to dissolve the formazan crystals. The absorbance was detected under a Multiskan EX (Thermo, Finland) at 470 nm (17).

BrdU Assay

Cell proliferation was analyzed by bromodeoxyuridine (BrdU) assay. Transfected cells were implanted into six-well plates at a density of 2 × 10⁵ cells/well. After incubation for 72 h, a final concentration of 10 μM BrdU labeling solution (Sigma-Aldrich) was added to each well and cultured for 4 h at 37°C. Finally, 150 μl of dimethyl sulfoxide (DMSO) was used to dissolve the formazan crystals. The absorbance was detected under a Multiskan EX (Thermo, Finland) at 470 nm (17).

Apoptosis Assay

Cell apoptosis was measured by Annexin-V/fluorescein isothiocyanate (FTTC) Apoptosis Detection Kit (BD Biosciences), according to the manuals. Briefly, the transfected cells were harvested and suspended in 100 μl of annexin-binding buffer. Then 10 μl of annexin V/FTTC (20 μg/ml) was added to the cells and incubated on ice in dark for 15 min; 400 μl of phosphate-buffered saline (PBS) and 5 μl of propidium iodide (PI, 50 μg/ml) were added to the cells and immediately detected under flow cytometry.

Western Blot

Transfected cells were collected and lysed in lysis buffer (Beyotime, Beijing, China). Protein concentration was determined using bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL, USA), and protein samples were separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to nitrocellulose membrane (Whatman, Dassel, Germany). After blocking with 5% nonfat milk for 2 h, the membranes were incubated with the primary antibodies overnight, and horseradish peroxidase-conjugated secondary antibody was used for 2 h. Finally, protein bands were visualized using the enhanced chemiluminescence (ECL) reagent (GE Healthcare, Little Chalfont, UK), and optical density was calculated by ImageJ software version 1.49 (National Institutes of Health, Bethesda, MD, USA).

Antibodies used were as follows: actin (C-2) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). p27 (ab54563), p21 (ab80633), Bcl-2 (ab692), Bax (ac32503), cleaved caspase 3 (ab32042), procaspase 3 (ab2171), and horseradish peroxidase-conjugated anti-mouse (ab6785) and anti-rabbit antibodies (ab6721) were purchased from Abcam (Cambridge, MA, USA).

Statistical Analysis

Data were presented as means ± standard derivation (SD). GraphPad Prism 5 software (GraphPad, San Diego, CA, USA) and one-way analysis of variance (ANOVA) were used to analyze the significant difference between groups. Values of p < 0.05 were considered statistically significant.

RESULTS

Effects of miR-16-1 on A549 Cell Proliferation

In order to reveal the function of miR-16-1 on NSCLC cell proliferation, miR-16-1 mimics or inhibitors were transfected into A549 cells to promote or suppress the expression of miR-16-1. After transfection, cells were cultured for 1–5 days, and then cell proliferation was measured by MTT assay (Fig. 1A) and BrdU assay (Fig. 1B). We found that cell proliferation was significantly reduced by miR-16-1 overexpression (p < 0.01 or p < 0.001), whereas it was significantly promoted by miR-16-1 suppression (p < 0.01) when compared with the control group. These results indicated that miR-16-1...
overexpression could inhibit cell proliferation, while miR-16-1 suppression could promote cell proliferation.

**miR-16-1 Affects A549 Cell Proliferation via Regulating the Expression of p27**

In order to understand the possible molecular mechanisms of miR-16-1 on NSCLC cell proliferation, the expression changes of proliferation-related factors, p27 and p21, were detected by Western blot. As shown in Figure 2A and B, the expression level of p27 was significantly upregulated by miR-16-1 overexpression ($p<0.001$) and was significantly downregulated by miR-16-1 suppression ($p<0.05$) when compared with the control group. However, the expression level of p21 was not significantly regulated by miR-16-1 overexpression or suppression. These results revealed that the inhibitive effects of miR-16-1 on A549 cells might be involved in the protein expression of p27, but not p21.

**Figure 1.** miR-16-1 overexpression suppressed A549 cell proliferation. miR-16-1 mimics, inhibitors, or control was transfected into A549 cells, and then cell proliferation was determined by MTT analysis (A) and BrdU assay (B). MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide; BrdU+, bromodeoxyuridine positive. **$p<0.01$; ***$p<0.001$.

**Figure 2.** miR-16-1 overexpression suppressed A549 cell proliferation via regulating the expression of p27. (A, B) miR-16-1 mimics, inhibitors, or control was transfected into A549 cells, and then the expression levels of p27 and p21 in cells were detected by Western blot. *$p<0.05$; ***$p<0.001$; NS, no significance.
Effects of miR-16-1 on A549 Cell Apoptosis

In order to test the effects of miR-16-1 on NSCLC cell apoptosis, the transfected cells were stained by two fluorescent dyes, annexin V/FITC and PI, and then cell apoptosis was detected under flow cytometry. Results in Figure 3A and B showed that miR-16-1 overexpression significantly increased the apoptosis rate ($p<0.001$), whereas miR-16-1 suppression significantly decreased the apoptosis rate ($p<0.01$), when compared with the control group. These results revealed that miR-16-1 overexpression could induce cell apoptosis, while miR-16-1 suppression could inhibit cell apoptosis.

miR-16-1 Affects A549 Cell Apoptosis via Regulating the Expression of Bcl-2, Bax, and Caspase 3

To understand the possible molecular mechanisms of miR-16-1 on NSCLC cell apoptosis, the expression changes of apoptosis-related factors, Bcl-2, Bax, procaspase 3, and cleaved caspase 3, were detected by Western blot (Fig. 4A and B). We found that the expression level of Bcl-2 was significantly downregulated by miR-16-1 overexpression ($p<0.001$) and upregulated by miR-16-1 suppression ($p<0.001$), when compared with the control group. However, expression levels of Bax, procaspase 3, and cleaved caspase 3 were significantly upregulated by miR-16-1 overexpression ($p<0.001$) and downregulated by miR-16-1 suppression ($p<0.05$, $p<0.001$, and $p<0.01$) when compared with the control group. Thus, the inductive effects of miR-16-1 on A549 cells might be involved in the protein expressions of Bcl-2, Bax, and caspase 3.

DISCUSSION

NSCLC is a problem worldwide and accounts for over 80% of all lung cancer cases (2). Many miRs have been reported to be associated with the initiation and progression of NSCLC by regulating their target genes (9–11). However the roles of miR-16-1 in NSCLC have not yet

![Figure 3](image-url)
been reported. In this study, miR-16-1 in A549 cells was overexpressed or suppressed by transfection with miR-16-1 mimics or inhibitors. We found that miR-16-1 overexpression could inhibit cell proliferation and induce apoptosis in A549 cells. Besides, the protein expressions of p27, Bax, procaspase 3, and cleaved caspase 3 were upregulated, the expression of Bcl-2 was suppressed, and the expression of p21 was unaffected by overexpression of miR-16-1. However, the impact of miR-16-1 suppression on A549 cell proliferation, apoptosis, and protein expressions was completely opposite to miR-16-1 overexpression.

Increasing reports have recognized miRs as important posttranscriptional regulators of gene expression in cancer cells (13). They have been shown to play vital roles in many cancers by regulating the expression of oncogenes and tumor suppressor genes (19). miR-16-1 belongs to the miR-16 cluster and is located at chromosome 13q14 (13). A recent study has identified that it acts as a tumor suppressor gene in cancer via regulating cell proliferation and apoptosis in vitro (20). Bonci et al. reported that, in advanced prostate cancer cells, knockdown of miR-16-1 promoted survival and proliferation and reduced cell apoptosis (21). Our results were partly consistent with the previous studies in that miR-16-1 acted as a tumor suppressor via the controlling of cell proliferation and apoptosis. This is the first report demonstrating that miR-16-1 could inhibit proliferation and induce apoptosis in NSCLC cells.

The cyclin-dependent kinase inhibitors (CDKIs) play a well-established role in the regulation of the cell cycle (22). In the Cip/Kip family of proteins, p27 and p21 are two members of CDKIs, and they bind to and inhibit the activity of the cyclin-dependent kinases, which are involved in the negative control of cell cycle progression (23,24). Upregulation of p27 and p21 leads to arrest of cells in the G1 phase and blocks cell proliferation. Studies have indicated that the expression of p27 and p21 is inversely correlated with cell proliferation in a variety of carcinomas (25,26), including NSCLC (27). In this study, miR-16-1 overexpression upregulated the protein expression of p27, whereas it could not significantly regulate the expression of p21; thus, we inferred that miR-16-1 overexpression reduced proliferation through upregulating the expression of p27.

Bcl-2 family proteins are key regulators of cell apoptosis (28–30). The prosurvival subfamily members, such as Bcl-2, Bcl-XL, and Bcl-w, are central players in the genetic program of eukaryotic cells favoring survival by inhibiting cell apoptosis (31). While the proapoptotic subfamily members, such as Bax, Bak and Bok, are critical to unleash the effector phase of apoptosis (32), usually Bcl-2 family proteins cleave caspases and then induce cell apoptosis and affect cellular destruction (31). Caspase 3 is one of the downstream proteins of the Bcl-2 family proteins, and the cleaved caspase 3 is the one that ultimately executes the apoptosis (33). Evidence from in vitro and in vivo studies showed that activation of caspase 3, downregulation of Bcl-2, and upregulation of Bax resulted in the induction of NSCLC cell apoptosis (34). Anagnostou et al. have also confirmed that inhibition of Bcl-2 induces mitochondrial apoptosis via activating and cleaving caspases (35). In this study, we found that the overexpression of miR-16-1 downregulated the expression of Bcl-2.
and upregulated the expression of Bax, procaspase 3, and cleaved caspase 3, implying that miR-16-1 overexpression could induce apoptosis through regulating the expression of Bcl-2, Bax, and caspase 3 in NSCLC cells.

Taken together, the inhibitive effects of miR-16-1 overexpression on cell proliferation and the inductive effects of miR-16-1 overexpression on cell apoptosis in NSCLC cells were verified. p27, Bcl-2, Bax, and cleaved caspase 3, implying that miR-16-1 overexpression could induce apoptosis through regulating the expression of cyclin E1 (CCNE1) gene expression in human cervical cancer cells. Int. J. Clin. Exp. Med. 8:15999–16006; 2015.

REFERENCES

1. Zhang, H.; Duan, J.; Qu, Y.; Deng, T.; Liu, R.; Zhang, L.; Bai, M.; Li, J.; Ning, T.; Ge, S.; Wang, X.; Wang, Z.; Fan, Q.; Li, H.; Ying, G.; Huang, D.; Ba, Y. Onco-miR-24 regulates cell growth and apoptosis by targeting BCL2L11 in gastric cancer. Protein Cell 7:141–151; 2016.
2. Ourari-Dhahir, B.; Ben Slima, H.; Ben Amar, J.; El Gharbi, L.; Ali, M.; Baccar Azzabi, S.; Aouina, H.; Bouacha, H. Management of non small cell lung cancer. Tunis Med. 90:847–851; 2012.
3. Farhat, F. S.; Houhou, W. Targeted therapies in non-small cell lung carcinoma: What have we achieved so far? Ther. Adv. Med. Oncol. 5:249–270; 2013.
4. Vilmar, A. C.; Sorensen, J. B. Customising chemotherapy in advanced nonsmall cell lung cancer: Daily practice and perspectives. Eur. Respir. Rev. 20:45–52; 2011.
5. J.M.; Elizabeth, H. B. Drug resistance mechanisms in non-small cell lung carcinoma. J. Can. Res. Updates. 2:265–282; 2013.
6. Ge, X.; Liu, X.; Lin, F.; Li, P.; Liu, K.; Geng, R.; Dai, C.; Lin, Y.; Yang, G.; Wu, Z.; Chang, J.; Lu, J.; Li. J. MicroRNA-421 regulated by HIF-1α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase 3 in gastric cancer. Oncotarget. 2016. [Epub ahead of print]
7. Mirmajidi, S. H.; Najafi, M.; Mirmajidi, S. T.; Nasr Nasrabadi, N. Study of regulatory promoter polymorphism (-248 G>A) of Bax gene in patients with gastric cancer in the northern provinces of Iran. Gastroenterol. Hepatol. Bed Bench. 9:36–44; 2016.
8. Garzon, R.; Calin, G. A.; Croce, C. M. MicroRNAs in cancer. Annu. Rev. Med. 60:167–179; 2009.
9. Kwan, J. Y.; Psarianos, P.; Bruce, J. P.; Yip, K. W.; Liu, F. F. The complexity of microRNAs in human cancer. J. Radiat. Res. pii: rrw009; 2016. [Epub ahead of print]
10. Sun, C.; Li, S.; Yang, C.; Xi, Y.; Wang, L.; Zhang, F.; Li, D. MicroRNA-187-3p mitigates non-small cell lung cancer (NSCLC) development through down-regulation of BCL6. Biochem. Biophys. Res. Commun. 471:82–88; 2016.
11. Nishijima, N.; Seike, M.; Soeno, C.; Chiba, M.; Miyanaga, A.; Noro, R.; Sugano, T.; Matsumoto, M.; Kubota, K.; Gemma, A. miR-200-ZEB axis regulates sensitivity to ninetanib in non-small cell lung cancer cells. Int. J. Oncol. 48:937–944; 2016.
12. Chen, C.; Chen, C.; Chen, J.; Zhou, L.; Xu, H.; Jin, W.; Wu, J.; Shenmeng, G. Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer. Mol. Cell. Biochem. 383:137–148; 2013.
13. Zubilaga-Guerrero, M. I.; Alarcón-Romero Ldel, C.; Illades-Aguir, B.; Flores-Alfar, E.; Bermúdez-Morales, V. H.; Deas, J.; Peralta-Zaragoza, O. MicroRNA miR-16-1 regulates CCNE1 (cyclin E1) gene expression in human cervical cancer cells. Int. J. Clin. Exp. Med. 8:15999–16006; 2015.
14. Kang, W.; Tong, J. H.; Lung, R. W.; Dong, Y.; Zhao, J.; Liang, Q.; Zhang, L.; Pan, Y.; Yang, W.; Pang, J. C.; Cheng, A. S.; Yu, J.; To, K. F. Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma. Mol. Cancer 14:52; 2015.
15. Azimi, A.; Hagh, M. F.; Talebi, M.; Yousefi, B.; Hosseinpour for feizi, A. A.; Baradaran, B.; Movassaghpoor, A. A.; Shamssasenjan, K.; Khanzedeh, T.; Ghaderi, A. H.; Heydabad, M. Z. Time- and concentration-dependent effects of resveratrol on miR 15a and miR16-1 expression and apoptosis in the CCRF-CEM acute lymphoblastic leukemia cell line. Asian J. Cancer Prev. 16:6463–6468; 2015.
16. Franks, S. E.; Jones, R. A.; Briah, R.; Murray, P.; Moorehead, R. A. BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549. BMC Res. Notes 9:134; 2016.
17. Ju, J. H.; Jang, K.; Lee, K. M.; Kim, M.; Kim, J.; Yi, J. Y.; Noh, D. Y.; Shin, I. CD24 enhances DNA damage-induced apoptosis by modulating NF-kB signaling in CD44-expressing breast cancer cells. Carcinogenesis 32:1474–1483; 2011.
18. Reischmann, P.; Fiebeck, J.; von der Weiden, N.; Müller, O. Measured effects of Wnt3a on proliferation of HEK293T cells depend on the applied assay. Int. J. Cell Biol. 928502; 2015.
19. Gregory, R. I.; Shiekhattar, R. MicroRNA biogenesis and cancer. Cancer Res. 65:3509–3512; 2005.
20. Wu, X.; Ding, B.; Gao, J.; Wang, H.; Fan, W.; Wang, X.; Zhang, W.; Wang, X.; Ye, L.; Zhang, M.; Ding, X.; Liu, Z.; Zhu, Q.; Gao, S. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int. J. Nanomedicine 6:1747–1756; 2011.
21. Bonci, D.; Coppola, V.; Musumeci, M.; Addario, A.; Giuffrida, R.; Memeo, L.; D’Urso, L.; Pagliuca, A.; Biffoni, M.; Labbaye, C.; Bartucci, M.; Muto, G.; Peschle, C.; De Maria, R. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 14:1271–1277; 2008.
22. Fei, Z.; Gao, Y.; Qiu, M.; Qi, X.; Dai, Y.; Wang, S.; Quan, Z.; Liu, Y.; Ou, J. Down-regulation of dihydrofolate reductase inhibits the growth of endothelial EA.hy926 cell through induction of G1 cell cycle arrest via up-regulating p53 and p21waf1/cip1 expression. J. Clin. Biochem. Nutr. 58:105–113; 2016.
23. Elledge, S. J.; Winston, J.; Harper, J. W. A question of balance: The role of cyclin-kinase inhibitors in development and tumorigenesis. Trends Cell Biol. 6:388–392; 1996.
24. Harper, J. W.; Elledge, S. J. Cdk inhibitors in development and cancer. Curr. Opin. Genet. Dev. 6:56–64; 1996.
25. Indovina, P.; Giorgi, F.; Rizzo, V.; Khadang, B.; Schenone, S.; Di Marzo, D.; Forte, I. M.; Tomei, V.; Mattioli, E.;
D’Urso, V.; Grilli, B.; Botta, M.; Giordano, A.; Pentimalli, F. New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization. Oncogene 31:929–938; 2012.

26. Cao, D.; Bromberg, P. A.; Samet, J. M. Diesel particle-induced transcriptional expression of p21 involves activation of EGFR, Src, and Stat3. Am. J. Respir. Cell Mol. Biol. 42:888–895; 2010.

27. Chen, B.; Xu, X.; Luo, J.; Wang, H.; Zhou, S. Rapamycin enhances the anti-cancer effect of dasatinib by suppressing Src/P3K/mTOR pathway in NSCLC cells. PLoS One 10:e0129663; 2015.

28. Brenner, D.; Mak, T. W. Mitochondrial cell death effectors. Curr. Opin. Cell Biol. 21:871–877; 2009.

29. Ghiotto, F.; Fais, F.; Bruno, S. BH3-only proteins: The death-puppeteer’s wires. Cytometry A 77:11–21; 2010.

30. Czabotar, P. E.; Lessene, G.; Strasser, A.; Adams, J. M. Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15:2014; 2014.

31. Cory, S.; Adams, J. M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2:647–656; 2002.

32. Ke, F.; Bouillet, P.; Kaufmann, T.; Strasser, A.; Kerr, J.; Voss, A. K. Consequences of the combined loss of BOK and BAK or BOK and BAX. Cell Death Dis. 6:e650; 2013.

33. Zimmermann, K. C.; Bonz, C.; Green, D. R. The machinery of programmed cell death. Pharmacol. Ther. 92:57–70; 2001.

34. Pal, H. C.; Sharma, S.; Strickland, L. R.; Agarwal, J.; Athar, M.; Elmer, C. A.; Afaq, F. Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways. PLoS One 8:e72770; 2013.

35. Anagnostou, V. K.; Lowery, F. J.; Zolota, V.; Tzelepi, V.; popcornath, A.; Liceaga, C.; Panagopoulos, N.; Frangia, K.; Tanne, L.; Boffa, D.; Gettinger, S.; Detterbeck, F.; Homer, R. J.; Dougenis, D.; Rimm, D. L.; Syrigos, K. N. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 9:186; 2010.